CXCR4 antagonists are small-molecule which block the CXCR4 receptors and prevent their activation. Blocking the receptors stop the receptors' ligand, CXCL12, from binding which prevent downstream effects. CXCR4 antagonists are especially important for hindering cancer progression because one of the downstream effects initiated by CXCR4 receptor activation is cell movement which lead to tumor growth and metastasis in cancer patients. The CXCR4 receptor has been targeted by antagonistic substances, these antagonists have prospective use as therapeutic drug agents, and are currently under development in labs worldwide.
This report contains market size and forecasts of CXCR4 Antagonists in Global, including the following market information:
Global CXCR4 Antagonists Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global CXCR4 Antagonists market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
BL-8040 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of CXCR4 Antagonists include Sanofi, BioLineRx, X4 Pharmaceuticals, Eli Lilly, Roche, Merck, Biokine Therapeutics, GlycoMimetics and Harmonic Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CXCR4 Antagonists companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CXCR4 Antagonists Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global CXCR4 Antagonists Market Segment Percentages, by Type, 2021 (%)
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Others
Global CXCR4 Antagonists Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global CXCR4 Antagonists Market Segment Percentages, by Application, 2021 (%)
Cancer
HIV
Chronic Inflammatory Diseases
Global CXCR4 Antagonists Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global CXCR4 Antagonists Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CXCR4 Antagonists revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies CXCR4 Antagonists revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
BioLineRx
X4 Pharmaceuticals
Eli Lilly
Roche
Merck
Biokine Therapeutics
GlycoMimetics
Harmonic Pharma
Upsher-Smith Laboratories